Can the State of Cancer Chemotherapy Resistance Be Reverted by Epigenetic Therapy?

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2006 Jul 13

PMID 16831224

Citations 12

Authors

Carlos Perez-Plasencia

Alfonso Duenas-Gonzalez

Affiliations

Soon will be listed here.

Abstract

Background: Transcriptome analysis shows that the chemotherapy innate resistance state of tumors is characterized by: poorly dividing tumor cells; an increased DNA repair; an increased drug efflux potential by ABC-transporters; and a dysfunctional ECM. Because chemotherapy resistance involves multiple genes, epigenetic-mediated changes could be the main force responsible of this phenotype. Our hypothesis deals with the potential role of epigenetic therapy for affecting the chemotherapy resistant phenotype of malignant tumors.

Presentation Of The Hypothesis: Recent studies reveal the involvement of DNA methylation and histone modifications in the reprogramming of the genome of mammalian cells in cancer. In this sense, it can be hypothesized that epigenetic reprogramming can participate in the establishment of an epigenetic mark associated with the chemotherapy resistant phenotype. If this were correct, then it could be expected that agents targeting DNA methylation and histone deacetylation would by reverting the epigenetic mark induce a global expression profile that mirror the observed in untreated resistant cells.

Testing The Hypothesis: It is proposed to perform a detailed analysis using all the available databases where the gene expression of primary tumors was analyzed and data correlated with the therapeutic outcome to determine whether a transcriptome profiling of "resistance" is observed. Assuming an epigenetic programming determines at some level the intrinsic resistant phenotype, then a similar pattern of gene expression dictated by an epigenetic mark should also be found in cell acquiring drug resistance. If these expectations are meet, then it should be further investigated at the genomic level whether these phenotypes are associated to certain patterns of DNA methylation and chromatin modification. Once confirmed the existence of an epigenetic mark associated to either the intrinsic or acquired chemotherapy resistant phenotype, then a causal association should be investigated. These preclinical findings should also be tested in a clinical setting.

Implications Of The Hypothesis: Our hypothesis on the ability of epigenetic therapy to revert the epigenetic changes leading to a transcritome profile that defines the resistant state will eventually be a more rational and effective way to treat malignant tumors.

Citing Articles

Understanding Cancer's Defense against Topoisomerase-Active Drugs: A Comprehensive Review.

Sharma N, Bahot A, Sekar G, Bansode M, Khunteta K, Sonar P Cancers (Basel). 2024; 16(4).

PMID: 38398072 PMC: 10886629. DOI: 10.3390/cancers16040680.

Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance.

Rytlewski J, Brockman Q, Dodd R, Milhem M, Monga V Cancer Drug Resist. 2022; 5(1):25-35.

PMID: 35582536 PMC: 8992584. DOI: 10.20517/cdr.2021.88.

Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia.

van Dijk A, Hoff F, Qiu Y, Chandra J, Jabbour E, de Bont E Clin Epigenetics. 2021; 13(1):21.

PMID: 33509276 PMC: 7841917. DOI: 10.1186/s13148-021-01011-x.

Stochastic tuning of gene expression enables cellular adaptation in the absence of pre-existing regulatory circuitry.

Freddolino L, Freddolino P, Yang J, Momen-Roknabadi A, Tavazoie S Elife. 2018; 7.

PMID: 29620524 PMC: 5919758. DOI: 10.7554/eLife.31867.

Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer.

Yin F, Wang N, Bi X, Yu X, Xu X, Wang Y Virol J. 2016; 13:60.

PMID: 27044426 PMC: 4820863. DOI: 10.1186/s12985-016-0515-5.

References

Hsiao H, Wang W, Chen P, Su Y . Overexpression of thymosin beta-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively. Carcinogenesis. 2005; 27(5):936-44. DOI: 10.1093/carcin/bgi316. View

Liu L, Taverna P, Whitacre C, Chatterjee S, Gerson S . Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res. 1999; 5(10):2908-17. View

Lage H . ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents. 2003; 22(3):188-99. DOI: 10.1016/s0924-8579(03)00203-6. View

Townsend D, Tew K . The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003; 22(47):7369-75. PMC: 6361125. DOI: 10.1038/sj.onc.1206940. View

Kim M, Blake M, Baek J, Kohlhagen G, Pommier Y, Carrier F . Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003; 63(21):7291-300. View

Mashima T, Tsuruo T . Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist Updat. 2005; 8(6):339-43. DOI: 10.1016/j.drup.2005.11.001. View

Sonnemann J, Kumar K, Heesch S, Muller C, Hartwig C, Maass M . Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol. 2006; 28(3):755-66. View

Dunn B . Hypomethylation: one side of a larger picture. Ann N Y Acad Sci. 2003; 983:28-42. DOI: 10.1111/j.1749-6632.2003.tb05960.x. View

Neumeister P, Albanese C, Balent B, Greally J, Pestell R . Senescence and epigenetic dysregulation in cancer. Int J Biochem Cell Biol. 2002; 34(11):1475-90. DOI: 10.1016/s1357-2725(02)00079-1. View

10.

Baker E, El-Osta A . The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res. 2003; 290(2):177-94. DOI: 10.1016/s0014-4827(03)00342-2. View

11.

Baker E, Johnstone R, Zalcberg J, El-Osta A . Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 2005; 24(54):8061-75. DOI: 10.1038/sj.onc.1208955. View

12.

Yap Y, Zhang X, Ling M, Wang X, Wong Y, Danchin A . Classification between normal and tumor tissues based on the pair-wise gene expression ratio. BMC Cancer. 2004; 4:72. PMC: 524507. DOI: 10.1186/1471-2407-4-72. View

13.

Weinstein I . Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis. 2000; 21(5):857-64. DOI: 10.1093/carcin/21.5.857. View

14.

Shi H, Wei S, Leu Y, Rahmatpanah F, Liu J, Yan P . Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 2003; 63(9):2164-71. View

15.

Nyce J . Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res. 1997; 386(2):153-61. DOI: 10.1016/s1383-5742(96)00051-8. View

16.

Teodoridis J, Strathdee G, Brown R . Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat. 2004; 7(4-5):267-78. DOI: 10.1016/j.drup.2004.06.005. View

17.

Al-Shahrour F, Minguez P, Vaquerizas J, Conde L, Dopazo J . BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res. 2005; 33(Web Server issue):W460-4. PMC: 1160217. DOI: 10.1093/nar/gki456. View

18.

Baylin S, Ohm J . Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006; 6(2):107-16. DOI: 10.1038/nrc1799. View

19.

Al-Shahrour F, Minguez P, Tarraga J, Montaner D, Alloza E, Vaquerizas J . BABELOMICS: a systems biology perspective in the functional annotation of genome-scale experiments. Nucleic Acids Res. 2006; 34(Web Server issue):W472-6. PMC: 1538844. DOI: 10.1093/nar/gkl172. View

20.

Sergent C, Franco N, Chapusot C, Lizard-Nacol S, Isambert N, Correia M . Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins. Cancer Chemother Pharmacol. 2002; 49(6):445-52. DOI: 10.1007/s00280-002-0450-6. View